Note 10 - Stockholders Equity (Details) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended	39 Months Ended					9 Months Ended	3 Months Ended			1 Months Ended	3 Months Ended		1 Months Ended			1 Months Ended							1 Months Ended		9 Months Ended	12 Months Ended						0 Months Ended	9 Months Ended	12 Months Ended		9 Months Ended	12 Months Ended		9 Months Ended	12 Months Ended		1 Months Ended											3 Months Ended
	Mar. 31, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2013	Aug. 25, 2013	Aug. 24, 2013	May 31, 2013	Dec. 31, 2012	Sep. 30, 2013 As Result of Securities Purchase Agreement [Member] Immune Pharmaceuticals Ltd. [Member] Ordinary Shares [Member]	Jun. 30, 2013 As Result of Securities Purchase Agreement [Member] Immune Pharmaceuticals Ltd. [Member]	Sep. 30, 2013 In Result of AntiDilution Securities Agreement, Merger Price Agreement [Member] Immune Pharmaceuticals Ltd. [Member] Ordinary Shares [Member]	Sep. 30, 2013 In Result of AntiDilution Securities Agreement, Merger Price Agreement [Member] Immune Pharmaceuticals Ltd. [Member]	Mar. 31, 2011 Investment Agreement, Amount of Equity Financing to be Raised by Immune Ltd [Member]	Sep. 30, 2013 Series A Convertible Preferred Stock [Member]	Sep. 30, 2013 Series B Convertible Preferred Stock (Member)	Mar. 31, 2011 Private Investor [Member] Ordinary Shares [Member]	Mar. 31, 2011 Private Investor [Member]	Dec. 31, 2012 Potential Share Buy-Back [Member] Immune Pharmaceuticals Ltd. [Member]	Oct. 31, 2010 Daniel Teper [Member] Ordinary Shares [Member]	Jul. 31, 2010 Daniel Teper [Member] Ordinary Shares [Member]	Aug. 25, 2013 Daniel Teper [Member] Reverse Merger [Member]	Aug. 25, 2013 Shareholders 1 [Member] Series A Preferred Stock [Member] Reverse Merger [Member]	Aug. 25, 2013 Shareholders 1 [Member] Reverse Merger [Member]	Aug. 25, 2013 Shareholders 2 [Member] Series A Preferred Stock [Member] Reverse Merger [Member]	Aug. 25, 2013 Shareholders 2 [Member] Reverse Merger [Member]	Dec. 31, 2010 Immune Pharmaceuticals Ltd. [Member] Ordinary Shares [Member] Founder [Member]	Dec. 31, 2010 Immune Pharmaceuticals Ltd. [Member] Ordinary Shares [Member]	Sep. 30, 2013 Immune Pharmaceuticals Ltd. [Member] Ordinary Shares [Member]	Dec. 31, 2012 Immune Pharmaceuticals Ltd. [Member] Ordinary Shares [Member]	Dec. 31, 2011 Immune Pharmaceuticals Ltd. [Member] Ordinary Shares [Member]	Dec. 31, 2012 Immune Pharmaceuticals Ltd. [Member] Ordinary Shares [Member] Minimum [Member]	Dec. 31, 2011 Immune Pharmaceuticals Ltd. [Member] Ordinary Shares [Member] Minimum [Member]	Dec. 31, 2012 Immune Pharmaceuticals Ltd. [Member] Ordinary Shares [Member] Maximum [Member]	Dec. 31, 2011 Immune Pharmaceuticals Ltd. [Member] Ordinary Shares [Member] Maximum [Member]	Aug. 25, 2013 Immune Pharmaceuticals Ltd. [Member] Reverse Merger [Member]	Sep. 30, 2013 Immune Pharmaceuticals Ltd. [Member]	Dec. 31, 2012 Immune Pharmaceuticals Ltd. [Member]	Dec. 31, 2011 Immune Pharmaceuticals Ltd. [Member]	Sep. 30, 2013 Immune Pharmaceuticals Ltd. [Member] Minimum [Member]	Dec. 31, 2012 Immune Pharmaceuticals Ltd. [Member] Minimum [Member]	Dec. 31, 2011 Immune Pharmaceuticals Ltd. [Member] Minimum [Member]	Sep. 30, 2013 Immune Pharmaceuticals Ltd. [Member] Maximum [Member]	Dec. 31, 2012 Immune Pharmaceuticals Ltd. [Member] Maximum [Member]	Dec. 31, 2011 Immune Pharmaceuticals Ltd. [Member] Maximum [Member]	Jul. 31, 2012 Chief Executive Officer [Member] Series A Preferred Stock [Member]	Jul. 31, 2012 Chief Executive Officer [Member] Ordinary Shares [Member]	Jun. 30, 2012 Chief Executive Officer [Member] Ordinary Shares [Member]	Oct. 31, 2010 Chief Executive Officer [Member] Ordinary Shares [Member]	Jun. 30, 2012 Chief Executive Officer [Member] Founder Shares [Member]	Jun. 30, 2012 Chief Executive Officer [Member]	Sep. 30, 2013 Undesignated [Member]	Sep. 30, 2013 Ordinary Shares [Member]	Dec. 31, 2012 Ordinary Shares [Member]	Sep. 30, 2013 Founder Shares [Member]	Dec. 31, 2012 Founder Shares [Member]	Sep. 30, 2013 Approximation [Member]
Note 10 - Stockholders Equity (Details) [Line Items]
Preferred Stock, Shares Authorized		5,000,000		5,000,000	5,000,000				5,000,000																																											4,996,935	0	92,500,000	0	4,500,000
Common Stock, Shares, Issued		13,276,037		13,276,037	13,276,037	13,276,037			0													4,173,150		1,563,964		4,752,976
Founder Shares, Shares, Outstanding																						6,750,000
Preferred Stock, Shares Issued		0		0	0				0														2,529,685		7,675,360																												0	4,806,132	0	4,500,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						1,041,409		500,000
(in Dollars)		$ 734,000	$ 0	$ 734,000	$ 734,000																																																				$ 700,000
Stock Issued During Period, Shares, New Issues (in Shares)										268,000		257,381					138,434			4,000,000	500,000						1,000,000	800,000	1,933,417	702,273	1,814,740					10,490,090													4,000,000
Shares Issued, Price Per Share (in Dollars per share)																													$ 2.40			$ 2.00	$ 1.00	$ 2.50	$ 2.00
Class of Warrant or Right, Issued																																					1,187,942	209,619	626,540
Proceeds from Issuance or Sale of Equity (in Dollars)															400,000																						4,400,000	1,200,000	2,480,143
Convertible Debt, Fair Value Disclosures (in Dollars)																																					1,000,000		464,248
Fair Value Assumptions, Expected Volatility Rate																																					91.90%	76.80%	101.10%
Fair Value Assumptions, Risk Free Interest Rate																																								0.36%	0.30%	0.40%	0.42%	0.40%	1.30%
Fair Value Assumptions, Expected Dividend Rate																																					0.00%	0.00%	0.00%
Fair Value Assumptions, Expected Term																																					3 years	3 years	3 years
Deemed Dividend On Issuance Of Antidilution Provisions (in Dollars)											500,000
Merger Price, Percent of Price Per Share													80.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)																																						2.50	1.83
Other Liabilities, Current (in Dollars)									150,000										150,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners						19.00%	19.00%											6.67%
Equity Financing, Required Amount to be Raised (in Dollars)														3,000,000
Stock Issued During Period, Value, New Issues (in Dollars)																	$ 200,000											$ 700,000
Debt Conversion, Converted Instrument, Shares Issued	142,830																																															408,809			408,809
Conversion of Stock, Shares Converted																																															2,529,685	4,500,000
Conversion of Stock, Shares Issued																																														2,529,685				4,500,000
Common Stock, Shares Authorized		225,000,000		225,000,000	225,000,000				225,000,000							225,000,000
Common Stock, Shares, Outstanding		13,276,037		13,276,037	13,276,037	13,276,037			0